The Non-Malignant Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Long-term results of the BELIEVE study: luspatercept in patients with beta-thalassemia
Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, shares some long-term results from the Phase III BELIEVE study (NCT02604433) evaluating the safety and efficacy of luspatercept in patients with transfusion-dependent beta-thalassemia. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Member of the advisory board for Celgene and BMS
